Paris - Advicenne (Euronext Growth - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases (the 'Company'), announces the results of the capital increase by issue of new ordinary shares with the maintenance of the shareholders' preferential subscription right announced on 11 September 2023.

This transaction raised EUR5.7 million by issuing 2,366,520 New Shares at a unit price of EUR2.41.

Philippe Boucheron, Deputy Chief Biotech at Bpifrance and Chairman of the Board of Directors of Advicenne, stated: 'We wanted to support Advicenne and its entire team, despite the particularly bad market situation. Investment opportunities in a commercial company in our sector are rare, especially in France. The teams were able to develop Sibnayal, market it and establish partnerships in Europe. They are now able to develop this product, greatly drifted, commercially and clinically in new indications, as well as in the United States. It was important that we were at their side and alongside other investors, especially Cemag Invest.'

Reminder of the purpose of the Capital Increase

The gross proceeds of the right issue amounted EUR 5,703,313.20. As stated in the presse release issued on September 11, 2023, funds will be allocated as follows: around 40% for the commercial development of Sibnayal, particularly in France and the UK, where Advicenne has direct sales operations; around 40% to optimize the industrial and clinical development of ADV7103; 20% to finance the Company's ongoing operations. Depuy

The Capital Increase was part of financing to enable the Company reaching operating profitability, may ensure the financing of Advicenne's anticipated cash requirements until the first quarter of 2025.

Contact:

Tel: +33 (0) 1 87 44 40 17

Email: investors@advicenne.com

(C) 2023 Electronic News Publishing, source ENP Newswire